title: Clinical relevance of human papillomavirus testing in cytopathology.
abstract: Cancer of the uterine cervix is the second most common cancer in women worldwide. Currently, cervical screening is based on cytology alone. Because infection with high-risk human papillomavirus types (hrHPVs) is a necessary cause of cervical cancer, it has been postulated that screening might become more efficient when it is based on combined cytology and hrHPV testing. In this review we will discuss the advantages of added HPV tests in cervical cancer screening, as a quality control for false-negative smears, in triage of women with equivocal smears, in follow-up of women treated for CIN3 or cervical cancer and for the detection of cervical adenocarcinoma.
authors.affiliation: Department of Pathology, Vrij Universiteit Medical Center, Amsterdam, The Netherlands.
authors.forename: A A T P
authors.initials: AA
authors.lastname: Brink
authors.forename: G D
authors.initials: GD
authors.lastname: Zielinski
authors.forename: R D M
authors.initials: RD
authors.lastname: Steenbergen
authors.forename: P J F
authors.initials: PJ
authors.lastname: Snijders
authors.forename: C J L M
authors.initials: CJ
authors.lastname: Meijer
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis; D003581:Cytodiagnosis / Q000379:methods; D005188:False Negative Reactions; D005260:Female; D006801:Humans; D008403:Mass Screening; D027383:Papillomaviridae / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000175:diagnosis*; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000517:prevention & control; D014626:Vaginal Smears; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis / Q000628:therapy